Research Reports | Market Assessment
June 2015

Psoriasis (Moderate to Severe) | Decision Base | US | 2015

With the Entry of New Oral and Biological Agents, Where Are the Remaining Areas of Opportunity in an Increasingly Crowded Market?

Affecting more than three million people in the major pharmaceutical markets, moderate to severe psoriasis represents a large market with substantial commercial opportunity. However, competition is set to intensify with the recent launch of the first approved IL-17 inhibitor, secukinumab (Novartis’s Cosentyx), and other highly efficacious biologics in the late-stage pipeline. These agents’ efficacy on more-stringent measures of response (i.e., PASI 90 and PASI 100 response rates) and superior efficacy to current agents in head-to-head studies will significantly raise the bar for psoriasis therapies.

Login to access report
Back to all Market Assessment reports
Login to access report

launch Related Market Assessment Reports